Analysis: What Will Drive Pfizer’s Growth After Covid?

(Blue View) — Pfizer Inc., the world’s biggest drugmaker, has experienced a boom during the pandemic, driven by its popular Covid-19 vaccines and treatments. But as Covid wanes, the challenges facing the company are expanding, raising concerns about its business outlook.

Over the past two years, Pfizer topped global pharmaceutical companies by sales. The company’s non-Covid pharmaceutical business expanded by less than 3%. Pfizer has also been struggling to sustain growth of newly acquired businesses and to catch up with rivals in development of innovative biotech medicines.